Insider Selling: G1 Therapeutics, Inc. (NASDAQ:GTHX) CEO Sells $19,231.62 in Stock

G1 Therapeutics, Inc. (NASDAQ:GTHX) CEO John E. (Jack) Jr. Bailey sold 7,662 shares of G1 Therapeutics stock in a transaction on Friday, July 5th. The shares were sold at an average price of $2.51, for a total value of $19,231.62. Following the completion of the transaction, the chief executive officer now owns 549,674 shares of the company’s stock, valued at approximately $1,379,681.74. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

G1 Therapeutics Stock Up 4.9 %

Shares of G1 Therapeutics stock opened at $2.79 on Thursday. The company has a quick ratio of 2.55, a current ratio of 2.94 and a debt-to-equity ratio of 1.34. G1 Therapeutics, Inc. has a 12 month low of $1.08 and a 12 month high of $6.14. The business has a fifty day simple moving average of $3.37 and a 200 day simple moving average of $3.56. The stock has a market cap of $145.86 million, a PE ratio of -4.50 and a beta of 1.53.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. The company had revenue of $14.48 million for the quarter, compared to analyst estimates of $15.21 million. During the same period last year, the firm earned ($0.53) earnings per share. Research analysts predict that G1 Therapeutics, Inc. will post -0.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Wedbush reiterated an “outperform” rating and issued a $3.00 price objective (down previously from $5.00) on shares of G1 Therapeutics in a research report on Monday, June 24th. Needham & Company LLC lowered their target price on G1 Therapeutics from $12.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, June 25th. Finally, HC Wainwright lowered their target price on G1 Therapeutics from $9.00 to $3.00 and set a “buy” rating for the company in a research note on Tuesday, June 25th.

Institutional Investors Weigh In On G1 Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Financial Advocates Investment Management bought a new position in G1 Therapeutics during the fourth quarter worth about $39,000. SG Americas Securities LLC bought a new stake in shares of G1 Therapeutics in the first quarter valued at about $58,000. Capstone Investment Advisors LLC bought a new stake in shares of G1 Therapeutics in the fourth quarter valued at about $76,000. Jump Financial LLC bought a new stake in shares of G1 Therapeutics in the fourth quarter valued at about $105,000. Finally, Choreo LLC bought a new stake in shares of G1 Therapeutics in the fourth quarter valued at about $107,000. 24.21% of the stock is owned by institutional investors and hedge funds.

About G1 Therapeutics

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.